For the quarter ending 2026-03-31, VRDN has $789,017K in assets. $153,009K in debts.
| Balance Sheets | 2026-03-31 | 2025-09-30 | 2025-06-30 | |
|---|---|---|---|---|
| Cash and cash equivalents | 176,346 | 169,647 | 117,324 | |
| Marketable securities | 585,835 | 321,254 | 446,032 | |
| Unbilled revenue | - | 70,000 | - | |
| Prepaid expenses and other current assets | 22,563 | 11,012 | 15,394 | |
| Total current assets | 784,744 | 571,913 | 578,750 | |
| Property and equipment, net | 1,130 | 1,125 | 1,091 | |
| Operating lease right-of-use asset | 2,255 | 2,582 | 1,977 | |
| Other assets | 888 | 1,518 | 506 | |
| Total assets | 789,017 | 577,138 | 582,324 | |
| Current portion of long-term debt | - | - | 8,435 | |
| Current portion of deferred revenue - related party | - | - | 288 | |
| Accounts payable | 13,313 | 10,063 | 8,518 | |
| Long-term debt | - | 20,890 | 12,353 | |
| Accrued liabilities | 38,492 | 40,633 | 35,344 | |
| Total current liabilities | 51,805 | 50,696 | 52,585 | |
| Long-term debt, net | 50,436 | - | - | |
| Derivative liability | 12,500 | - | - | |
| Liability related to the sale of future revenue, net | 36,092 | - | - | |
| Other liabilities | 2,176 | 2,582 | 2,077 | |
| Deferred revenue - related party | - | - | 140 | |
| Total liabilities | 153,009 | 74,168 | 67,155 | |
| Preferred stock-Series APreferred Stock | 61,188 | 61,188 | 61,188 | |
| Preferred stock-Series BPreferred Stock | 70,868 | 127,697 | 127,697 | |
| Common stock, 0.01 par value 200,000,000 shares authorized 102,458,094 and 101,826,500 shares issued and outstanding as of march31, 2026 and december31, 2025, respectively | 1,025 | 822 | 817 | |
| Additional paid-in capital | 1,946,844 | 1,531,003 | 1,508,902 | |
| Accumulated other comprehensive income (loss) | -558 | 363 | 69 | |
| Accumulated deficit | -1,443,359 | -1,218,103 | -1,183,504 | |
| Total stockholders equity | 636,008 | 502,970 | 515,169 | |
| Total liabilities and stockholders equity | 789,017 | 577,138 | 582,324 | |
Viridian Therapeutics, Inc. DE (VRDN)
Viridian Therapeutics, Inc. DE (VRDN)